GlaxoSmithKline Plc (GSK)

44.09
0.24 0.55
NYSE : Health Technology
Prev Close 43.85
Open 43.43
Day Low/High 43.41 / 44.12
52 Wk Low/High 36.41 / 46.01
Volume 2.30M
Avg Volume 2.37M
Exchange NYSE
Shares Outstanding 2.49B
Market Cap 109.12B
EPS 2.00
P/E Ratio 25.20
Div & Yield 2.00 (4.47%)
More Companies Pull Advertising to Protest Google's Treatment of Extremist Content

More Companies Pull Advertising to Protest Google's Treatment of Extremist Content

Britain is the second largest market for Google, generating $7.8 billion primarily from advertising in 2016.

Still Bullish on GlaxoSmithKline

Still Bullish on GlaxoSmithKline

After another technical look at GSK, this FTSE component is still going strong.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Why I'm Optimistic About GlaxoSmithKline

Why I'm Optimistic About GlaxoSmithKline

Check out GSK's well developed base pattern.

Gilead Has 'Good News' But is it Enough?

Gilead Has 'Good News' But is it Enough?

Gilead Sciences' bictegravir suppressed HIV better than rival Glaxo's dolutegravir.

3 Stocks Poised for Gains Under the Donald Trump Era

3 Stocks Poised for Gains Under the Donald Trump Era

With stocks at record highs, there are still buying opportunities, but investors should be selective.

Now That Dow Has Hit 20,000, GM and Nike Are Hot Stocks

Now That Dow Has Hit 20,000, GM and Nike Are Hot Stocks

Some of Wall Street's biggest stocks are teetering on the edge of breakout territory this week. Here are five of them.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

These companies show signs of a change of direction.

Tracing Benjamin Graham's Descendants

Tracing Benjamin Graham's Descendants

Firms' 13F filings show how they've followed in the footsteps of the father of value investing.

Donald Trump Election Victory Boosts Some Stocks and Sectors

Donald Trump Election Victory Boosts Some Stocks and Sectors

As we all know, the stock market and the economy abhor uncertainty.

Cramer: Don't Just Stand There Like Bambi; Sell Some

Cramer: Don't Just Stand There Like Bambi; Sell Some

Stocks in the health care sector seem to have no underpinnings whatsoever.

Cramer: Credibility Is a Precious Market Commodity

Cramer: Credibility Is a Precious Market Commodity

And if it's lost, good luck getting it back.

What to Watch This Week: Apple Earnings, Third Quarter GDP

What to Watch This Week: Apple Earnings, Third Quarter GDP

For the week of October 24, investors await quarterly results from a slew of major companies, including Apple, along with the first estimate of third quarter GDP.

9 Stocks for the Bank of England's Corporate-Bond Purchases

9 Stocks for the Bank of England's Corporate-Bond Purchases

Which stocks will be most favored by the corporate-bond purchases?

4 Stocks to Buy in This Vulnerable Market

4 Stocks to Buy in This Vulnerable Market

This market is like a leaky helium balloon; watch out for sudden downdrafts.

Portfolio Roundup: Humira Helps Buoy AbbVie Shares

Portfolio Roundup: Humira Helps Buoy AbbVie Shares

The drug maker continued to rally Monday.

GlaxoSmithKline Inks Medical 'Bioelectronics' Partnership With Alphabet

GlaxoSmithKline Inks Medical 'Bioelectronics' Partnership With Alphabet

The pharmaceutical giant is teaming up with Google's parent with as much as $715 million in joint investments.

Morning Movers: GSK, GOOGL, SCTY, TSLA

Morning Movers: GSK, GOOGL, SCTY, TSLA

GlaxoSmithKline and Google's parent Alphabet announced their joint plan to pioneer a new form of electronic medical treatment.

Grab a Bit of Britain With FTSE 100 ETF

Grab a Bit of Britain With FTSE 100 ETF

The U.K. isn't going anywhere Brexit vote notwithstanding, and here's a way to get on the most business-friendly state across the pond.

European Stocks: What's Your Pain Tolerance?

If you think the best thing to do post-Brexit is buy more, here are 4 to consider.

GlaxoSmithKline Has No Cure for Sideways Action

GlaxoSmithKline Has No Cure for Sideways Action

GSK has been largely stuck between $44 on the upside and $37 on the downside for the past 12 months.

Sizing Up Johnson & Johnson's Talcum Fallout

Sizing Up Johnson & Johnson's Talcum Fallout

The expected legal deluge will be manageable thanks to JNJ's massive size and financial strength.

Jim Cramer Likes Johnson & Johnson, Allergan in the Pharma Sector

Jim Cramer Likes Johnson & Johnson, Allergan in the Pharma Sector

Jim Cramer says it you are going to own a drug stock, invest in Allergan or Johnson & Johnson.

Jim Cramer Says This Will Be a Good Quarter for 3-M, Buy GE on a Dip

Jim Cramer Says This Will Be a Good Quarter for 3-M, Buy GE on a Dip

Jim Cramer says UnitedHealth's stock is going much higher, and it is a 'terrific' name to own.

Glaxo, IP and PetMed Poised to Go Higher

Glaxo, IP and PetMed Poised to Go Higher

Shares of GlaxoSmithKline are up a pleasant 5% in 2016 and it currently sports a healthy 6.5% dividend yield.

Tax Clampdown Prompts Pfizer to Scrap Allergan Purchase

CEO Read says the Viagra maker retains the means to pursue 'attractive business development' opportunities as he tears up the six-month-old deal with the maker of Botox.

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top ten biopharmaceutical brands.

GlaxoSmithKline's Condition Isn't Improving

GlaxoSmithKline's Condition Isn't Improving

With the short-term trend neutral and the longer-term trend down be on guard for a break lower to around $35.

3 Pharma Stocks to Heal Your Portfolio

Dividend yield is the determining factor in this strategy.

Novice Trade: GlaxoSmithKline

Novice Trade: GlaxoSmithKline

Owning GSK May calls may give a nice payout on any good news regarding a Zika virus vaccine.